( Editorial: --> 8642 )
ZAGREB, Sept 7 (Hina) - Croatia's pharmaceutical giant Pliva on
Monday signed a licensing agreement with Receptron, Inc., a
California-based biotechnological company.
The agreement gives Pliva exclusive rights to the development of
medicines which act similarly to endogenous trombopoetine (TPO),
but have additional advantages as well.
In line with the agreement, Pliva will assist Receptron in
research, pay out exclusive rights and royalties from future
sales.
TPO is a growth agent which stimulates the production of blood
vessels.
It should also replace transfusions which are expensive and high-
risk due to possibilities of HIV and hepatitis infections.
It is expected the TPO product's market potential will be in excess
of US$500 million.
(hina) ha jn/sp
071640 MET sep 98
Izložba Otona Župančiča u Muzeju grada Zagreba
ZKM najavio izvedbu dramskog teksta "Sin, majka i otac sjede za stolom i dugo šute"
Gong Ministarstvu obrazovanja: Omogućite svim učenicima da uče o demokraciji
Bugarski parlament potvrdio novu vladu
HDZ: Sisačkim odgojiteljicama se nezakonito obračunavaju plaće
Inflacija u prosincu 3,4 posto - druga procjena
Renault blago povećao prodaju u 2024.
ISPRAVAK VIJESTI: Najava događaja - kultura - za četvrtak, 16. siječnja
Benetton zatvara tvornicu u Osijeku, otkaz za više od 260 radnika - sindikat
Čak 600 policajaca na ogledu košarkaške Eurolige u Parizu